NASDAQ: BDTXBlack Diamond Therapeutics Inc Stock
$5.06+0.05 (+1%)
Updated Apr 24, 2024
BDTX Price
$5.06
Fair Value Price
$0.70
Market Cap
$261.69M
52 Week Low
$1.43
52 Week High
$6.21
P/E
-2.69x
P/B
2.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$67M
Beta
1.24
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BDTX Overview
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BDTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDTX ($5.06) is overvalued by 619.24% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BDTX ($5.06) is not significantly undervalued (619.24%) relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BDTX due diligence checks available for Premium users.
Be the first to know about important BDTX news, forecast changes, insider trades & much more!
BDTX News
Valuation
BDTX fair value
Fair Value of BDTX stock based on Discounted Cash Flow (DCF)
Price
$5.06
Fair Value
$0.70
Overvalued by
619.24%
BDTX ($5.06) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BDTX ($5.06) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BDTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.69x
Industry
15.69x
Market
41.27x
BDTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.24x
Industry
5.86x
BDTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BDTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.4M
Profit Margin
0%
BDTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$158.6M
Liabilities
$41.8M
Debt to equity
0.36
BDTX's short-term assets ($134.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDTX's short-term assets ($134.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BDTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.0M
Investing
$12.2M
Financing
-$46.0k
BDTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDTX vs Biotech Stocks
Black Diamond Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.